Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Consensus Rating of “Moderate Buy” by Analysts

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has been given an average recommendation of “Moderate Buy” by the seventeen brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, fourteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $23.3571.

A number of research firms have recently commented on CMPS. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research note on Friday, July 17th. Wells Fargo & Company began coverage on shares of Compass Pathways in a research report on Monday, July 27th. They set an “equal weight” rating and a $13.00 price objective on the stock. Oppenheimer restated an “outperform” rating on shares of Compass Pathways in a research note on Wednesday, August 5th. Morgan Stanley lifted their target price on shares of Compass Pathways from $17.00 to $18.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Finally, BTIG Research upped their target price on shares of Compass Pathways from $14.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th.

Institutional Trading of Compass Pathways

Several institutional investors have recently added to or reduced their stakes in CMPS. Corient Private Wealth LLC increased its position in Compass Pathways by 3.2% during the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock valued at $265,000 after acquiring an additional 1,200 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after purchasing an additional 1,920 shares during the last quarter. Ancora Advisors LLC purchased a new position in Compass Pathways in the second quarter worth about $43,000. Conservest Capital Advisors Inc. boosted its position in Compass Pathways by 24.6% in the fourth quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock worth $175,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Compass Pathways during the 4th quarter valued at about $38,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

Compass Pathways Stock Performance

Shares of CMPS opened at $13.90 on Wednesday. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 0.60. The business’s 50 day moving average price is $12.72 and its 200-day moving average price is $9.68. Compass Pathways has a 52 week low of $3.97 and a 52 week high of $15.40. The stock has a market cap of $1.92 billion, a P/E ratio of -3.01 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). Equities research analysts anticipate that Compass Pathways will post -1.26 earnings per share for the current fiscal year.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.